Why the study?
Combined oral contraceptives are associated with increased cardiovascular risk, but the potential favorable cardiac effects of drospirenone compared with androgenic contraceptives have not been fully elucidated.
Does a contraceptive containing ethinyl estradiol and drospirenone prevent elevations in cardiac uric acid and PAI-1 compared to a levonorgestrel-containing contraceptive in female Wistar rats?
Does a contraceptive containing ethinyl estradiol and drospirenone prevent elevations in cardiac uric acid and PAI-1 compared to a levonorgestrel-containing contraceptive in female Wistar rats?
Drospirenone-containing oral contraceptives may offer a safer cardiovascular profile than levonorgestrel-containing ones by avoiding elevations in cardiac uric acid and PAI-1.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for drospirenone COC effects on PAI-1/GSK-3; human trials needed before clinical consideration.
The use of combined oral contraceptives (COC) have been associated with increased risk of adverse cardiovascular events and elevated cardiac and circulating plasminogen activator inhibitor-1 (PAI-1) and glycogen synthase kinase-3 (GSK-3) have been implicated in these events. Contraceptives containing drospirenone, a progestin with anti-androgenic actions may have a positive or neutral effect on cardiac PAI-1 and GSK-3 levels. Studies on the favorable effects of oral contraceptives containing drospirenone when compared with other androgenic contraceptives have not been fully elucidated. We therefore sought to compare the effect of a contraceptive containing ethinyl estradiol and drospirenone (DSP) with a contraceptive containing ethinyl estradiol and levonorgestrel (LVG) on cardiac uric acid (UA), PAI-1, GSK-3 and some hematological parameters. Ten weeks old female Wistar rats were divided into three groups; control (CON), LVG or DSP treated rats. The treatment lasted for 8 weeks. Results showed that LVG and not DSP treatment led to increase in plasma and cardiac tissue UA, plasma and cardiac PAI-1 as well as granulocyte-lymphocyte ratio (GLR) and platelet-lymphocyte ratio (PLR). However, the DSP treatment affected the circulating GSK-3. Taken together, the findings showed that LVG and not DSP affected cardiac UA and PAI-1. These results suggest that COC containing drospirenone appears to have positive effects on cardiac UA and PAI-1 levels but do not affect GSK-3, hence, COC containing drospirenone may be a better and safer means of contraception compared to androgenic contraceptives.
No takes yet. Share an insight, caveat, or question.
Adeyanju et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: